title: Immunological characterization and antibacterial function of persisting granulocytes in leukemic patients receiving pulse cytosine arabinoside-consolidation chemotherapy on days 1, 3, and 5.
abstract: High-dose cytosine arabinoside (HiDAC) and intermediate-dose cytosine arabinoside (IDAC) have been introduced as effective and safe consolidation chemotherapy in acute myeloid leukemia, with relatively low rates of life-threatening infections despite the high total dose of the cytostatic drug. To explore the biological background of low toxicity, we examined the numbers, immunophenotype, and functional properties of granulocytes in patients with acute myeloid leukemia receiving HiDAC or IDAC. Interestingly, the absolute numbers of neutrophils remained >500/microl until day 10 in 92 of 125 (74%) HiDAC cycles and in 106 of 113 (94%) IDAC cycles. As assessed by electron microscopy, these day-10 granulocytes surviving chemotherapy were found to be mature cells containing secondary granules and phagolysosomes. They also expressed opsonization- and phagocytosis-linked surface Ags (C3biR, CR1, C1qR, C5aR, FcgammaRI, FcgammaRII, FcgammaRIII, and G-CSF and GM-CSF receptors) like neutrophils in healthy controls. Moreover, these day-10 neutrophils exhibited oxidative burst activity and took up and digested bacteria in the same way as neutrophils in healthy controls. There was a negative correlation between absolute neutrophil counts and severe infections in HiDAC- and IDAC-treated patients with a later onset of infections in IDAC patients (median: IDAC, day 18; HiDAC, day 16). Together, functionally mature neutrophils are detectable at least until day 10 in patients treated with HiDAC or IDAC, and may explain the relatively low hematologic toxicity of these consolidation protocols. IDAC is a superior protocol in this regard and may therefore be most suitable for elderly patients and those at high risk for severe infections.
authors.affiliation: Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence in Clinical and Experimental Oncology, Vienna, Austria.
authors.forename: Maria-T
authors.initials: MT
authors.lastname: Krauth
authors.forename: Stefan
authors.initials: S
authors.lastname: Florian
authors.forename: Alexandra
authors.initials: A
authors.lastname: Böhm
authors.forename: Karoline
authors.initials: K
authors.lastname: Sonneck
authors.forename: Hermine
authors.initials: H
authors.lastname: Agis
authors.forename: Puchit
authors.initials: P
authors.lastname: Samorapoompichit
authors.forename: Alexander W
authors.initials: AW
authors.lastname: Hauswirth
authors.forename: Wolfgang R
authors.initials: WR
authors.lastname: Sperr
authors.forename: Peter
authors.initials: P
authors.lastname: Valent
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000276:immunology*; D003561:Cytarabine / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006098:Granulocytes / Q000276:immunology* / Q000382:microbiology / Q000648:ultrastructure; D006801:Humans; D016130:Immunophenotyping; D007951:Leukemia, Myeloid / Q000276:immunology* / Q000382:microbiology; D008297:Male; D009504:Neutrophils / Q000276:immunology / Q000382:microbiology / Q000648:ultrastructure; D013997:Time Factors
chemical_list: D003561:Cytarabine